Abstract:Background: The treatment of lung adenocarcinoma (LUAD) has been stuck in a bottleneck due to a number of factors. There is a pressing need for research into potential genetic markers to help drug development and improve the prognosis of patients. SLC2A1 has been reported in multiple LUAD-related prognosis prediction signatures. However, the role of SLC2A1 in the occurrence and development of WAD and its impact on prognosis remain elusive. Methods: The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were used to acquire the samples. We used R to perform statistical analysis, Gene Set Enrichment Analysis (GSEA), immune infiltration and immune cell correlation analysis, drug sensitivity analysis, and visualization. The immune cell score was calculated using the Timer2.0 database. Prognostic analysis was performed using R, Gene Expression Profiling Interactive Analysis (GEPIA), and the Kaplan-Meier Plotter. Overall survival and progression free survival were the main outcome of prognosis analysis. Protein-protein interaction, disease-genetics analysis, and tissue-specific enrichment analyses were performed using Metascape. Results: SLC2A1 was highly expressed in LUAD tissues. Univariate COX regression [hazard ratio (HR) = 1.689, 95% confidence interval (CI): 1.242-2.249, P<0.001] and multivariate COX regression including age, gender, smoking, TNM stage and SLC2A1 expression (HR = 1.567, 95% CI: 1.127-2.179, P=0.008) showed that SLC2A1 was an independent prognostic risk factor for LUAD. GSEA and Metascape analysis showed that SLC2A1 was strongly associated with the cell cycle, mitosis, lung tissue, and tumor recurrence. Immune correlation analysis showed that SLC2A1 was associated with two tumor infiltration immune cells: activated CD (cluster of differentiation)4* memory T cells (r=0.31, P=0.003) and activated mast cells (r=-0.28, P=0.010). Moreover, patients with high SLC2A1 expression had higher immune checkpoint molecules and Tumor Immune Dysfunction and Exclusion (TIDE) scores, indicating poorer immunotherapy efficacy. Patients with high SLC2A1 expression were more sensitive to chemotherapy drugs and less sensitive to targeted drugs compared to those with low SLC2A1 expression. Conclusions: The high expression of SLC2A1 in LUAD predicted poor prognosis and was closely related to tumor immunity, which could be used as an effective prognostic biomarker to provide a new strategy for clinical prognosis assessment and immunotherapy for LUAD.

Title SETDB 1 accelerates tumourigenesis by regulating the WNT signalling pathway

Identification of Key Genes and Evaluation of Clinical Outcomes in Lung Squamous Cell Carcinoma Using Integrated Bioinformatics Analysis

Setdb1 Accelerates Tumourigenesis by Regulating the Wnt Signalling Pathway

Aberrant Expression of SCARA5 in Lung Adenocarcinoma and its Clinical Significance

The prognostic value of AGR2 expression in solid tumours: a systematic review and meta-analysis

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

Anterior Gradient Protein 2 Expression in High Grade Head and Neck Squamous Cell Carcinoma Correlated with Cancer Stem Cell and Epithelial Mesenchymal Transition

AGR2 is associated with gastric cancer progression and poor survival.

ADGRD1 as a Potential Prognostic and Immunological Biomarker in Non-Small-Cell Lung Cancer

Prevalence and Significance of AGR2 Expression in Human Cancer

Aberrant Expression of Proteins Involved in Signal Transduction and DNA Repair Pathways in Lung Cancer and Their Association with Clinical Parameters.

AGR2 Promotes the Proliferation, Migration and Regulates Epithelial-Mesenchymal Transition in Salivary Adenoid Cystic Carcinoma

AGR2 expression as a predictive biomarker for therapy response in esophageal squamous cell carcinoma

SLC2A1 Plays a Significant Prognostic Role in Lung Adenocarcinoma and is Associated with Tumor Immunity Based on Bioinformatics Analysis.

Overexpression of Teashirt Homolog 2 Suppresses Cell Proliferation and Predicts the Favorable Survival of Lung Adenocarcinoma

AGRN Promotes Lung Adenocarcinoma Progression by Activating Notch Signaling Pathway and Acts As a Therapeutic Target

Advanced Glycation End Products’ Receptor DNA Methylation Associated with Immune Infiltration and Prognosis of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

High Expression Levels of CDK1 and CDC20 in Patients With Lung Squamous Cell Carcinoma are Associated With Worse Prognosis

A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non-Small Cell Lung Cancer Patients

AGR2 – a Novel Predictor of Neoadjuvant Chemoradiotherapy Response in Esophageal Squamous Cell Carcinoma

Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy